STAT3 and neoplasm: Combined use of the HDAC3 inhibitor RGFP966 and the BET inhibitor JQ1 was found to significantly suppress GSC proliferation, drive apoptosis, inhibit tumor growth in vivo, and synergistically disrupt the Gli1/IL6/STAT3 axis [77, 294].